Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Hans-Willi Breuer Added: 3 years ago
Epidemiology has repeatedly shown that elevated levels of cholesterol play a key role in the development of atherosclerotic disease. In particular, low density lipoprotein (LDL) cholesterol has been strongly associated with coronary heart disease (CHD) risk.1-5 Lowering LDL cholesterol reduces the incidence of atherosclerotic disease, irrespective of how the reduction is achieved. The efficacy of… View more
Author(s): Hans-Willi Breuer Added: 3 years ago
Abstract Studies have consistently shown that coronary heart disease (CHD) risk is correlated closely with low density lipoprotein (LDL) cholesterol levels. The lower the LDL cholesterol, the lower the cardiovascular (CV) risk; however, there is a question over how much LDL cholesterol lowering is low enough and what supporting evidence there is for this. This article reviews recent evidence in… View more
Author(s): Esther Godfrey , Julian PJ Halcox Added: 3 years ago
Atherosclerotic cardiovascular disease (CVD) is a global epidemic. As life expectancy has increased, chronic degenerative diseases have become a significant healthcare burden, affecting developed and developing countries alike,1 with atherosclerotic disease the leading cause of death according to the WHO.2 The development of effective strategies for the prevention of cardiovascular events at… View more
Added: 2 months ago Source:  Radcliffe Cardiology, Greg Guillory
In a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However, until recently, its… View more
Author(s): Konstantinos Tziomalos , Dimitri P Mikhailidis Added: 3 years ago
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide.1 The relationship between coronary heart disease (CHD) and elevated low-density lipoprotein cholesterol (LDL-C) levels is well established.2 Several large-scale trials, in both primary and secondary prevention settings, have shown that lowering LDL-C levels using statins substantially reduces cardiovascular… View more
Author(s): Salim S Virani , Ankur Kalra Added: 1 year ago
This week’s Parallax episode is focusing on the latest science and questions surrounding one of the conundrums of cardiovascular science: Lipoprotein(a). Dr. Ankur Kalra invites Dr Salim S Virani to help simplify the concept of Lp(a) with answering key questions about its measurement and its place in practice and prevention. Dr Virani is a Professor at Baylor College of Medicine, Director of the… View more
Author(s): Alberico L Catapano Added: 3 years ago
The strong positive correlation between plasma low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) mortality has been documented beyond any doubt.1 A large body of trials aiming at reducing elevated LDL-C levels also shows that therapeutic intervention results in a proportional reduction of CV events independent of the type of intervention (i.e. diet versus drugs or… View more
Author(s): Charles Amir German , Michael D Shapiro Added: 3 years ago
Cardiovascular disease (CVD) is the leading cause of mortality in the world, accounting for 17.9 million deaths per year and 31% of deaths worldwide.1 In addition to the toll on human life, the healthcare cost of CVD continues to grow, with estimates of up to US$1.1 trillion by 2035.1 Given the significant public health burden of disease as well as the cost of healthcare, we must shift our focus… View more
Author(s): Anandita Agarwala , Michael D Shapiro Added: 3 years ago
Atherogenic dyslipidaemia encompasses a broad variety of lipid phenotypes. While LDL cholesterol is a well-known risk factor for atherosclerotic cardiovascular disease (ASCVD), there are additional atherogenic lipoproteins that may be targeted to further reduce ASCVD risk. In their comprehensive review, Lorenzatti and Toth emphasise that, even when LDL cholesterol levels are optimised, ASCVD… View more
Author(s): Steven E Nissen , Maryam Barkhordarian Added: 5 months ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is… View more